Roman Bradel, Ph.D. has served as our Vice President of Regulatory Affairs since March 2024. Dr. Bradel possesses over 30 years of industry experience, including 25 years in positions of regulatory leadership and offers a very diverse regulatory background with experience in all dosage forms of pharmaceuticals, their respective submissions, and clinical paths.
Previous leadership roles included serving as the Head of Regulatory Affairs for both Oryn Therapeutics, and Prolacta Bioscience. Dr. Bradel was also responsible for supporting Humira® (adalumimab) during his tenure with AbbVie Inc. Dr. Bradel holds a B.S. in Physical Chemistry and earned his Ph.D. in Chemistry from the Technical University Berlin, in Berlin, Germany, with his thesis focused on Biopolymers for controlled-release pharmaceuticals.